Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts

12.04.24 00:00 Uhr

Werte in diesem Artikel
Aktien

48,35 EUR 0,65 EUR 1,36%

Indizes

PKT PKT

1.622,5 PKT 7,5 PKT 0,46%

524,0 PKT 2,2 PKT 0,43%

27.240,9 PKT 183,2 PKT 0,68%

27.281,5 PKT 157,2 PKT 0,58%

13.462,1 PKT 76,8 PKT 0,57%

7.395,0 PKT 32,1 PKT 0,44%

Puma Biotech (PBYI) closed the most recent trading day at $5.49, moving -0.63% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.74%. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq gained 1.68%.Prior to today's trading, shares of the biopharmaceutical company had gained 3.66% over the past month. This has outpaced the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8% in that time.The investment community will be paying close attention to the earnings performance of Puma Biotech in its upcoming release. The company's upcoming EPS is projected at -$0.16, signifying a 277.78% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $41.53 million, down 21.34% from the year-ago period.For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.51 per share and a revenue of $220.22 million, signifying shifts of -23.88% and -6.57%, respectively, from the last year.Any recent changes to analyst estimates for Puma Biotech should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 15.69% lower. At present, Puma Biotech boasts a Zacks Rank of #4 (Sell).In the context of valuation, Puma Biotech is at present trading with a Forward P/E ratio of 10.9. This valuation marks a discount compared to its industry's average Forward P/E of 23.42.Also, we should mention that PBYI has a PEG ratio of 1.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.9 at the close of the market yesterday.The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Puma Biotechnology, Inc. (PBYI): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Biotech

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Biotech

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu PUMA SE

Analysen zu PUMA SE

DatumRatingAnalyst
17.05.2024PUMA SE Equal WeightBarclays Capital
10.05.2024PUMA SE BuyHauck Aufhäuser Lampe Privatbank AG
10.05.2024PUMA SE BuyWarburg Research
10.05.2024PUMA SE Sector PerformRBC Capital Markets
09.05.2024PUMA SE BuyDeutsche Bank AG
DatumRatingAnalyst
10.05.2024PUMA SE BuyHauck Aufhäuser Lampe Privatbank AG
10.05.2024PUMA SE BuyWarburg Research
09.05.2024PUMA SE BuyDeutsche Bank AG
09.05.2024PUMA SE BuyGoldman Sachs Group Inc.
08.05.2024PUMA SE AddBaader Bank
DatumRatingAnalyst
17.05.2024PUMA SE Equal WeightBarclays Capital
10.05.2024PUMA SE Sector PerformRBC Capital Markets
09.05.2024PUMA SE NeutralUBS AG
09.05.2024PUMA SE NeutralUBS AG
09.05.2024PUMA SE NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
20.09.2021PUMA SE VerkaufenDZ BANK
06.07.2021PUMA SE VerkaufenDZ BANK
28.04.2021PUMA SE VerkaufenDZ BANK
23.04.2021PUMA SE VerkaufenDZ BANK
09.04.2021PUMA SE VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für PUMA SE nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"